TechForce Robotics Expands Into Pharmaceutical Automation With LIM-E Robot Deployment at Oncotelic Therapeutics

TechForce Robotics, Inc., the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics. This deployment fulfills Phase 1 objectives under a joint development agreement designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows. The move marks the company's first operational entry into pharmaceutical and laboratory automation, expanding beyond its hospitality roots.

Laboratory and pharmaceutical operations increasingly face challenges similar to those that have accelerated automation across industries from manufacturing to hospitality. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work, product development, or manufacturing output. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows.

TechForce Robotics is positioning itself to address that opportunity by extending its Robotics-as-a-Service (RaaS) platform into laboratory automation. The LIM-E robot is designed to handle routine tasks such as transporting samples, supplies, and equipment within laboratory environments, allowing highly trained personnel to focus on higher-value activities. The company's strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications in pharmaceutical settings.

According to the press release, the initial deployment at Oncotelic Therapeutics is a critical step in validating the LIM-E robot's capabilities in a real-world pharmaceutical environment. The joint development agreement focuses on evaluating robotics and AI-enhanced systems for compliance with Good Manufacturing Practices (GMP), which are essential for pharmaceutical production. Successful completion of these evaluations could open the door to broader adoption across the pharmaceutical industry.

TechForce Robotics' expansion into pharmaceutical automation reflects a broader trend of technology companies leveraging their expertise to address specialized industry needs. The company's background in hospitality robotics, where it developed systems for food service and logistics, provided foundational experience in autonomous navigation, task execution, and human-robot interaction. Applying these capabilities to laboratory automation requires additional considerations for precision, cleanliness, and regulatory compliance, which the partnership with JJ Enterprise helps address.

Investors can find the latest news and updates relating to NGTF in the company's newsroom at https://ibn.fm/NGTF. The announcement was distributed by TechMediaWire, a specialized communications platform focused on pioneering technology companies. TechMediaWire is part of the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions. More information is available at https://www.TechMediaWire.com.

This deployment represents a significant milestone for TechForce Robotics as it diversifies its RaaS platform into a high-growth sector with stringent regulatory requirements. The implications extend beyond the company itself, as successful integration of autonomous robots in pharmaceutical laboratories could lead to increased efficiency, reduced human error, and improved scalability for drug development and manufacturing processes.